| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cognitive Dysfunction | 23 | 2023 | 333 | 8.040 |
Why?
|
| Brain | 38 | 2023 | 4113 | 3.870 |
Why?
|
| Cognition Disorders | 24 | 2018 | 786 | 3.750 |
Why?
|
| Cognition | 24 | 2023 | 968 | 3.650 |
Why?
|
| Nerve Net | 12 | 2017 | 257 | 3.610 |
Why?
|
| Cancer Survivors | 13 | 2022 | 650 | 3.520 |
Why?
|
| Connectome | 8 | 2022 | 112 | 2.910 |
Why?
|
| Breast Neoplasms | 31 | 2022 | 15694 | 2.720 |
Why?
|
| Executive Function | 9 | 2020 | 160 | 2.560 |
Why?
|
| Turner Syndrome | 10 | 2011 | 68 | 2.100 |
Why?
|
| Meditation | 5 | 2021 | 73 | 1.830 |
Why?
|
| Magnetic Resonance Imaging | 47 | 2023 | 7702 | 1.760 |
Why?
|
| Music | 3 | 2021 | 36 | 1.720 |
Why?
|
| Neural Pathways | 7 | 2021 | 298 | 1.660 |
Why?
|
| Survivors | 11 | 2021 | 1031 | 1.650 |
Why?
|
| Prefrontal Cortex | 9 | 2020 | 229 | 1.530 |
Why?
|
| Brain Mapping | 10 | 2021 | 644 | 1.440 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 6 | 2021 | 134 | 1.380 |
Why?
|
| Neuropsychological Tests | 22 | 2022 | 1178 | 1.340 |
Why?
|
| Antineoplastic Agents | 16 | 2023 | 14289 | 1.090 |
Why?
|
| Cerebral Cortex | 7 | 2020 | 621 | 1.000 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2020 | 2796 | 0.980 |
Why?
|
| Intelligence | 9 | 2015 | 126 | 0.920 |
Why?
|
| White Matter | 2 | 2016 | 195 | 0.900 |
Why?
|
| Task Performance and Analysis | 3 | 2016 | 136 | 0.880 |
Why?
|
| Female | 87 | 2023 | 141928 | 0.840 |
Why?
|
| Choline | 2 | 2013 | 76 | 0.790 |
Why?
|
| Hematologic Neoplasms | 3 | 2022 | 1870 | 0.790 |
Why?
|
| Memory | 6 | 2019 | 429 | 0.780 |
Why?
|
| Humans | 110 | 2023 | 261506 | 0.780 |
Why?
|
| Adult | 50 | 2023 | 77950 | 0.770 |
Why?
|
| Aging | 4 | 2020 | 1582 | 0.760 |
Why?
|
| Schools | 1 | 2021 | 233 | 0.720 |
Why?
|
| Biological Products | 1 | 2023 | 274 | 0.710 |
Why?
|
| Sleep Wake Disorders | 3 | 2018 | 348 | 0.710 |
Why?
|
| Cytokines | 2 | 2019 | 2809 | 0.700 |
Why?
|
| Multiple Sclerosis | 1 | 2022 | 349 | 0.650 |
Why?
|
| Mental Health | 1 | 2021 | 415 | 0.630 |
Why?
|
| Brain Neoplasms | 5 | 2022 | 4849 | 0.620 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 246 | 0.620 |
Why?
|
| Neurocognitive Disorders | 1 | 2018 | 69 | 0.620 |
Why?
|
| tau Proteins | 1 | 2019 | 216 | 0.620 |
Why?
|
| Middle Aged | 35 | 2022 | 86204 | 0.610 |
Why?
|
| Infant, Premature | 6 | 2009 | 787 | 0.600 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2023 | 393 | 0.580 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2018 | 1648 | 0.570 |
Why?
|
| Neurofeedback | 1 | 2016 | 19 | 0.550 |
Why?
|
| Verbal Learning | 1 | 2016 | 84 | 0.540 |
Why?
|
| Neoplasms | 11 | 2023 | 15193 | 0.540 |
Why?
|
| Aged | 28 | 2022 | 70117 | 0.530 |
Why?
|
| Health Promotion | 3 | 2023 | 502 | 0.530 |
Why?
|
| Machine Learning | 1 | 2018 | 319 | 0.530 |
Why?
|
| Quality of Life | 13 | 2023 | 4532 | 0.500 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 598 | 0.490 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 4314 | 0.490 |
Why?
|
| Adolescent | 28 | 2021 | 31252 | 0.490 |
Why?
|
| Astrocytoma | 1 | 2016 | 321 | 0.480 |
Why?
|
| Hippocampus | 3 | 2012 | 915 | 0.480 |
Why?
|
| Child | 32 | 2021 | 29154 | 0.480 |
Why?
|
| Inositol | 1 | 2013 | 27 | 0.480 |
Why?
|
| Anthracyclines | 1 | 2016 | 331 | 0.470 |
Why?
|
| Temporal Lobe | 4 | 2009 | 192 | 0.470 |
Why?
|
| Monosomy | 2 | 2004 | 95 | 0.470 |
Why?
|
| Frontal Lobe | 6 | 2017 | 187 | 0.450 |
Why?
|
| Rest | 1 | 2013 | 71 | 0.450 |
Why?
|
| Young Adult | 18 | 2021 | 21445 | 0.440 |
Why?
|
| Chromosomes, Human, X | 2 | 2004 | 192 | 0.430 |
Why?
|
| Diffusion Tensor Imaging | 4 | 2021 | 303 | 0.430 |
Why?
|
| Fragile X Syndrome | 2 | 2015 | 150 | 0.430 |
Why?
|
| Male | 49 | 2023 | 123000 | 0.430 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2016 | 480 | 0.430 |
Why?
|
| Sexual and Gender Minorities | 2 | 2023 | 63 | 0.420 |
Why?
|
| Longitudinal Studies | 5 | 2022 | 1945 | 0.420 |
Why?
|
| Neuroimaging | 3 | 2021 | 403 | 0.420 |
Why?
|
| Models, Neurological | 2 | 2013 | 225 | 0.410 |
Why?
|
| Mathematical Concepts | 1 | 2011 | 13 | 0.410 |
Why?
|
| Aptitude | 1 | 2011 | 11 | 0.410 |
Why?
|
| Parietal Lobe | 5 | 2020 | 66 | 0.400 |
Why?
|
| Neurons | 4 | 2017 | 2287 | 0.400 |
Why?
|
| Sleep | 6 | 2021 | 413 | 0.400 |
Why?
|
| Cognitive Reserve | 1 | 2010 | 4 | 0.390 |
Why?
|
| Glioma | 1 | 2022 | 1963 | 0.390 |
Why?
|
| Brain Injuries | 2 | 2011 | 787 | 0.380 |
Why?
|
| Pilot Projects | 7 | 2021 | 2803 | 0.380 |
Why?
|
| Mindfulness | 2 | 2022 | 58 | 0.370 |
Why?
|
| Spermine Synthase | 1 | 2009 | 6 | 0.350 |
Why?
|
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2009 | 71 | 0.340 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 4298 | 0.340 |
Why?
|
| Case-Control Studies | 12 | 2020 | 6100 | 0.330 |
Why?
|
| Fragile X Mental Retardation Protein | 1 | 2009 | 126 | 0.320 |
Why?
|
| Memory Disorders | 2 | 2014 | 295 | 0.320 |
Why?
|
| Dyslexia | 3 | 2013 | 24 | 0.310 |
Why?
|
| Interleukin-6 | 1 | 2012 | 1038 | 0.310 |
Why?
|
| Coffin-Lowry Syndrome | 1 | 2007 | 5 | 0.300 |
Why?
|
| Small-Conductance Calcium-Activated Potassium Channels | 1 | 2007 | 14 | 0.300 |
Why?
|
| Language | 3 | 2017 | 309 | 0.300 |
Why?
|
| Treatment Outcome | 13 | 2021 | 32848 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 1538 | 0.290 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2020 | 15862 | 0.280 |
Why?
|
| Depressive Disorder | 3 | 2015 | 557 | 0.270 |
Why?
|
| Doxorubicin | 3 | 2017 | 3005 | 0.260 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2021 | 6550 | 0.260 |
Why?
|
| Software | 1 | 2012 | 1321 | 0.260 |
Why?
|
| Intelligence Tests | 5 | 2011 | 88 | 0.250 |
Why?
|
| Spatial Behavior | 1 | 2004 | 20 | 0.240 |
Why?
|
| Amygdala | 2 | 2008 | 127 | 0.240 |
Why?
|
| Language Development Disorders | 1 | 2005 | 167 | 0.240 |
Why?
|
| Fatigue | 3 | 2019 | 1239 | 0.240 |
Why?
|
| Orientation | 1 | 2004 | 57 | 0.240 |
Why?
|
| Child, Preschool | 9 | 2021 | 16273 | 0.240 |
Why?
|
| Biomarkers | 4 | 2021 | 5047 | 0.230 |
Why?
|
| Feasibility Studies | 3 | 2020 | 2292 | 0.230 |
Why?
|
| Infant, Premature, Diseases | 1 | 2005 | 245 | 0.220 |
Why?
|
| Psychological Theory | 1 | 2003 | 47 | 0.220 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2023 | 113 | 0.220 |
Why?
|
| Transgender Persons | 1 | 2023 | 55 | 0.210 |
Why?
|
| Apolipoproteins E | 1 | 2023 | 221 | 0.210 |
Why?
|
| Manganese | 1 | 2022 | 80 | 0.210 |
Why?
|
| Leukemia | 1 | 2011 | 1635 | 0.210 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 10331 | 0.210 |
Why?
|
| Oxygen | 2 | 2018 | 754 | 0.210 |
Why?
|
| Cerebellum | 2 | 2020 | 449 | 0.200 |
Why?
|
| Wakefulness | 1 | 2022 | 150 | 0.200 |
Why?
|
| School Health Services | 1 | 2021 | 109 | 0.200 |
Why?
|
| Retrospective Studies | 6 | 2022 | 37905 | 0.190 |
Why?
|
| Mutation | 3 | 2016 | 15179 | 0.190 |
Why?
|
| Minority Groups | 1 | 2023 | 322 | 0.190 |
Why?
|
| Statistics, Nonparametric | 2 | 2018 | 980 | 0.190 |
Why?
|
| Self Report | 3 | 2021 | 756 | 0.190 |
Why?
|
| Developmental Disabilities | 1 | 2005 | 674 | 0.190 |
Why?
|
| Ambulatory Care Facilities | 1 | 2022 | 289 | 0.180 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2005 | 925 | 0.180 |
Why?
|
| Psychomotor Performance | 2 | 2011 | 233 | 0.180 |
Why?
|
| Cranial Irradiation | 2 | 2021 | 315 | 0.180 |
Why?
|
| Thalamus | 1 | 2020 | 132 | 0.180 |
Why?
|
| Follow-Up Studies | 6 | 2023 | 14889 | 0.180 |
Why?
|
| Oxidative Stress | 2 | 2017 | 1129 | 0.180 |
Why?
|
| Verbal Behavior | 2 | 2009 | 62 | 0.170 |
Why?
|
| Suicidal Ideation | 1 | 2021 | 207 | 0.170 |
Why?
|
| Students | 1 | 2021 | 324 | 0.170 |
Why?
|
| Burnout, Professional | 1 | 2022 | 205 | 0.170 |
Why?
|
| Polyneuropathies | 1 | 2018 | 28 | 0.170 |
Why?
|
| Drug Therapy | 1 | 2019 | 205 | 0.170 |
Why?
|
| Anisotropy | 3 | 2015 | 181 | 0.160 |
Why?
|
| Functional Neuroimaging | 2 | 2020 | 38 | 0.160 |
Why?
|
| Protons | 1 | 2021 | 473 | 0.160 |
Why?
|
| Telomerase | 1 | 2021 | 525 | 0.160 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 275 | 0.160 |
Why?
|
| Wernicke Area | 1 | 2017 | 11 | 0.160 |
Why?
|
| Internet | 1 | 2022 | 706 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2019 | 267 | 0.150 |
Why?
|
| Peroxisomes | 1 | 2017 | 49 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2021 | 1021 | 0.150 |
Why?
|
| Physical Conditioning, Animal | 1 | 2018 | 112 | 0.140 |
Why?
|
| Visual Perception | 2 | 2009 | 154 | 0.140 |
Why?
|
| Comorbidity | 3 | 2018 | 2352 | 0.140 |
Why?
|
| Piracetam | 1 | 2016 | 11 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2021 | 12873 | 0.140 |
Why?
|
| Mental Processes | 1 | 2016 | 53 | 0.140 |
Why?
|
| Speech | 1 | 2017 | 133 | 0.140 |
Why?
|
| Rats | 6 | 2022 | 6086 | 0.140 |
Why?
|
| Neurogenesis | 1 | 2018 | 238 | 0.130 |
Why?
|
| California | 1 | 2016 | 208 | 0.130 |
Why?
|
| Perception | 1 | 2017 | 350 | 0.130 |
Why?
|
| Cerebral Hemorrhage | 2 | 2007 | 183 | 0.130 |
Why?
|
| Organ Size | 3 | 2020 | 690 | 0.130 |
Why?
|
| Sense of Coherence | 1 | 2014 | 3 | 0.130 |
Why?
|
| Phenotype | 2 | 2021 | 6295 | 0.130 |
Why?
|
| Exercise Therapy | 1 | 2017 | 288 | 0.130 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2016 | 246 | 0.130 |
Why?
|
| Goals | 1 | 2016 | 185 | 0.130 |
Why?
|
| Disability Evaluation | 1 | 2016 | 249 | 0.120 |
Why?
|
| Anorexia Nervosa | 1 | 2014 | 34 | 0.120 |
Why?
|
| Yoga | 1 | 2015 | 78 | 0.120 |
Why?
|
| Women's Health | 1 | 2016 | 205 | 0.120 |
Why?
|
| Restless Legs Syndrome | 1 | 2014 | 20 | 0.120 |
Why?
|
| Lysosomes | 1 | 2016 | 347 | 0.120 |
Why?
|
| Depression | 3 | 2019 | 1715 | 0.120 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2017 | 726 | 0.120 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2019 | 799 | 0.120 |
Why?
|
| Nerve Degeneration | 1 | 2015 | 148 | 0.120 |
Why?
|
| Cerebellar Neoplasms | 1 | 2018 | 434 | 0.120 |
Why?
|
| Infant, Very Low Birth Weight | 2 | 2005 | 165 | 0.120 |
Why?
|
| Testicular Neoplasms | 1 | 2017 | 529 | 0.120 |
Why?
|
| Survival | 1 | 2013 | 177 | 0.120 |
Why?
|
| Space Perception | 3 | 2009 | 77 | 0.110 |
Why?
|
| Texas | 2 | 2021 | 6311 | 0.110 |
Why?
|
| Support Vector Machine | 1 | 2013 | 44 | 0.110 |
Why?
|
| Nutrition Policy | 1 | 2014 | 111 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 502 | 0.110 |
Why?
|
| Medulloblastoma | 1 | 2018 | 540 | 0.110 |
Why?
|
| Infant, Newborn | 7 | 2009 | 8223 | 0.110 |
Why?
|
| Methotrexate | 2 | 2020 | 999 | 0.110 |
Why?
|
| Sex Factors | 4 | 2020 | 2139 | 0.110 |
Why?
|
| Dementia | 1 | 2018 | 453 | 0.110 |
Why?
|
| Data Interpretation, Statistical | 1 | 2015 | 482 | 0.110 |
Why?
|
| Gender Identity | 2 | 2023 | 75 | 0.110 |
Why?
|
| Pandemics | 1 | 2022 | 1559 | 0.110 |
Why?
|
| Paroxetine | 1 | 2012 | 34 | 0.110 |
Why?
|
| Wechsler Scales | 3 | 2011 | 26 | 0.110 |
Why?
|
| Articulation Disorders | 1 | 2011 | 3 | 0.100 |
Why?
|
| Synapses | 1 | 2016 | 509 | 0.100 |
Why?
|
| Abnormalities, Multiple | 2 | 2009 | 998 | 0.100 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2013 | 592 | 0.100 |
Why?
|
| Perceptual Disorders | 2 | 2009 | 14 | 0.100 |
Why?
|
| Choice Behavior | 1 | 2013 | 226 | 0.100 |
Why?
|
| Disease Progression | 1 | 2022 | 6682 | 0.100 |
Why?
|
| Home Care Services, Hospital-Based | 1 | 2011 | 5 | 0.100 |
Why?
|
| Algorithms | 1 | 2022 | 3890 | 0.100 |
Why?
|
| Time Factors | 3 | 2019 | 12926 | 0.100 |
Why?
|
| Pain | 1 | 2019 | 1658 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2004 | 2307 | 0.100 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2011 | 61 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2012 | 700 | 0.090 |
Why?
|
| Sexual Behavior | 2 | 2023 | 310 | 0.090 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.090 |
Why?
|
| User-Computer Interface | 1 | 2012 | 286 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 612 | 0.090 |
Why?
|
| Autophagy | 1 | 2016 | 927 | 0.090 |
Why?
|
| Injections, Spinal | 1 | 2010 | 257 | 0.090 |
Why?
|
| Cisplatin | 1 | 2017 | 2432 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2014 | 228 | 0.090 |
Why?
|
| Memory, Short-Term | 1 | 2011 | 160 | 0.090 |
Why?
|
| Infant | 2 | 2021 | 13310 | 0.090 |
Why?
|
| Hypoglycemia | 1 | 2011 | 213 | 0.090 |
Why?
|
| Exercise | 4 | 2018 | 1183 | 0.090 |
Why?
|
| Artificial Intelligence | 1 | 2013 | 388 | 0.090 |
Why?
|
| Birth Weight | 2 | 2009 | 374 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2021 | 4549 | 0.080 |
Why?
|
| Creatine | 1 | 2009 | 61 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 4938 | 0.080 |
Why?
|
| Language Development | 1 | 2009 | 30 | 0.080 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 7222 | 0.080 |
Why?
|
| Indans | 1 | 2009 | 68 | 0.080 |
Why?
|
| Social Perception | 1 | 2009 | 76 | 0.080 |
Why?
|
| Hyperglycemia | 1 | 2011 | 333 | 0.080 |
Why?
|
| Limbic System | 1 | 2008 | 29 | 0.080 |
Why?
|
| Mental Retardation, X-Linked | 1 | 2009 | 94 | 0.080 |
Why?
|
| Hydrocortisone | 1 | 2009 | 388 | 0.080 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2009 | 110 | 0.080 |
Why?
|
| DNA Damage | 1 | 2016 | 1954 | 0.080 |
Why?
|
| United States | 2 | 2023 | 15433 | 0.080 |
Why?
|
| Risk Factors | 5 | 2016 | 17523 | 0.080 |
Why?
|
| Face | 2 | 2007 | 273 | 0.080 |
Why?
|
| Indomethacin | 1 | 2007 | 91 | 0.080 |
Why?
|
| Practice Guidelines as Topic | 1 | 2018 | 2403 | 0.080 |
Why?
|
| Depressive Disorder, Major | 1 | 2013 | 441 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2021 | 5539 | 0.080 |
Why?
|
| Up-Regulation | 1 | 2013 | 2450 | 0.070 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2007 | 69 | 0.070 |
Why?
|
| Psychology | 1 | 2007 | 86 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2134 | 0.070 |
Why?
|
| Human Growth Hormone | 1 | 2007 | 82 | 0.070 |
Why?
|
| Cohort Studies | 1 | 2019 | 9244 | 0.070 |
Why?
|
| Genes, Dominant | 1 | 2007 | 331 | 0.070 |
Why?
|
| Computer Simulation | 1 | 2012 | 1529 | 0.070 |
Why?
|
| Genetic Carrier Screening | 1 | 2007 | 92 | 0.070 |
Why?
|
| Video Games | 1 | 2008 | 93 | 0.070 |
Why?
|
| Sensation Disorders | 1 | 2006 | 27 | 0.070 |
Why?
|
| Genomics | 1 | 2017 | 2738 | 0.070 |
Why?
|
| Alzheimer Disease | 1 | 2014 | 855 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2014 | 4320 | 0.070 |
Why?
|
| Premature Birth | 1 | 2011 | 407 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2015 | 901 | 0.070 |
Why?
|
| Heart Transplantation | 1 | 2013 | 908 | 0.070 |
Why?
|
| Skull | 1 | 2007 | 231 | 0.070 |
Why?
|
| Connecticut | 1 | 2005 | 33 | 0.070 |
Why?
|
| Linear Models | 2 | 2011 | 1085 | 0.070 |
Why?
|
| Child Development | 1 | 2008 | 255 | 0.070 |
Why?
|
| Syndrome | 1 | 2009 | 1351 | 0.070 |
Why?
|
| Risk Assessment | 2 | 2016 | 6869 | 0.070 |
Why?
|
| Mathematics | 1 | 2005 | 136 | 0.070 |
Why?
|
| Conserved Sequence | 1 | 2007 | 469 | 0.070 |
Why?
|
| Cerebral Ventricles | 1 | 2005 | 98 | 0.060 |
Why?
|
| Sex Characteristics | 2 | 2004 | 417 | 0.060 |
Why?
|
| Animals | 9 | 2022 | 59536 | 0.060 |
Why?
|
| Lateral Ventricles | 1 | 2004 | 26 | 0.060 |
Why?
|
| Williams Syndrome | 1 | 2004 | 37 | 0.060 |
Why?
|
| Radiography | 1 | 2009 | 1904 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2010 | 1299 | 0.060 |
Why?
|
| Models, Biological | 1 | 2013 | 3254 | 0.060 |
Why?
|
| Regression Analysis | 1 | 2007 | 1546 | 0.060 |
Why?
|
| Normal Distribution | 1 | 2004 | 61 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2017 | 5637 | 0.060 |
Why?
|
| Inflammation | 1 | 2014 | 2522 | 0.060 |
Why?
|
| Chromosome Deletion | 1 | 2009 | 1005 | 0.060 |
Why?
|
| Bone and Bones | 1 | 2007 | 619 | 0.060 |
Why?
|
| Gestational Age | 1 | 2007 | 1069 | 0.060 |
Why?
|
| Language Disorders | 1 | 2003 | 26 | 0.060 |
Why?
|
| Individuality | 2 | 2015 | 58 | 0.060 |
Why?
|
| Heterosexuality | 1 | 2023 | 11 | 0.060 |
Why?
|
| Piperidines | 1 | 2009 | 1035 | 0.060 |
Why?
|
| Movement Disorders | 1 | 2006 | 232 | 0.060 |
Why?
|
| Heart-Assist Devices | 1 | 2013 | 1171 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2011 | 830 | 0.060 |
Why?
|
| Photic Stimulation | 1 | 2004 | 259 | 0.050 |
Why?
|
| Prognosis | 3 | 2018 | 21713 | 0.050 |
Why?
|
| Glasgow Coma Scale | 1 | 2003 | 215 | 0.050 |
Why?
|
| Demography | 1 | 2004 | 435 | 0.050 |
Why?
|
| Long-Term Care | 1 | 2022 | 83 | 0.050 |
Why?
|
| Leucine Zippers | 1 | 2021 | 39 | 0.050 |
Why?
|
| Spectrum Analysis | 1 | 2022 | 139 | 0.050 |
Why?
|
| Educational Status | 1 | 2003 | 397 | 0.050 |
Why?
|
| Functional Laterality | 2 | 2017 | 316 | 0.050 |
Why?
|
| Mental Status and Dementia Tests | 1 | 2020 | 36 | 0.050 |
Why?
|
| Headache | 1 | 2021 | 163 | 0.050 |
Why?
|
| Language Tests | 2 | 2011 | 27 | 0.050 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2021 | 355 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 5112 | 0.040 |
Why?
|
| Empathy | 1 | 2020 | 101 | 0.040 |
Why?
|
| Mice | 4 | 2022 | 34495 | 0.040 |
Why?
|
| Behavior Therapy | 1 | 2021 | 298 | 0.040 |
Why?
|
| Stress, Psychological | 2 | 2017 | 1000 | 0.040 |
Why?
|
| Vinca Alkaloids | 1 | 2017 | 9 | 0.040 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 527 | 0.040 |
Why?
|
| Polysomnography | 1 | 2019 | 155 | 0.040 |
Why?
|
| Rats, Inbred F344 | 1 | 2018 | 224 | 0.040 |
Why?
|
| Social Isolation | 1 | 2017 | 64 | 0.040 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 183 | 0.040 |
Why?
|
| Sequestosome-1 Protein | 1 | 2016 | 39 | 0.040 |
Why?
|
| Autophagosomes | 1 | 2016 | 38 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2016 | 58 | 0.040 |
Why?
|
| Physical Examination | 1 | 2018 | 299 | 0.040 |
Why?
|
| Advisory Committees | 1 | 2018 | 203 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2020 | 629 | 0.040 |
Why?
|
| Lipid Droplets | 1 | 2016 | 49 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2020 | 1544 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2017 | 344 | 0.040 |
Why?
|
| Tumor Suppressor p53-Binding Protein 1 | 1 | 2016 | 87 | 0.040 |
Why?
|
| Neurites | 1 | 2016 | 63 | 0.030 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 330 | 0.030 |
Why?
|
| Heart Rate | 1 | 2019 | 737 | 0.030 |
Why?
|
| Dexamethasone | 1 | 2020 | 1450 | 0.030 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 29902 | 0.030 |
Why?
|
| Learning | 1 | 2018 | 403 | 0.030 |
Why?
|
| Organoplatinum Compounds | 1 | 2017 | 702 | 0.030 |
Why?
|
| Diet, Vegetarian | 1 | 2014 | 5 | 0.030 |
Why?
|
| Trans Fatty Acids | 1 | 2014 | 10 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 402 | 0.030 |
Why?
|
| Vitamin B 12 | 1 | 2014 | 73 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 215 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 967 | 0.030 |
Why?
|
| Surveys and Questionnaires | 2 | 2018 | 5687 | 0.030 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2016 | 316 | 0.030 |
Why?
|
| Vitamin E | 1 | 2014 | 136 | 0.030 |
Why?
|
| Animals, Newborn | 1 | 2018 | 1338 | 0.030 |
Why?
|
| Cell Death | 1 | 2016 | 671 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2014 | 95 | 0.030 |
Why?
|
| Neuroticism | 1 | 2013 | 5 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2016 | 493 | 0.030 |
Why?
|
| Internal-External Control | 1 | 2013 | 110 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2017 | 987 | 0.030 |
Why?
|
| Health Status | 1 | 2016 | 590 | 0.030 |
Why?
|
| Comprehension | 1 | 2013 | 120 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2014 | 247 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2014 | 448 | 0.020 |
Why?
|
| Fathers | 1 | 2011 | 68 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2016 | 2074 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2016 | 1620 | 0.020 |
Why?
|
| Environment | 1 | 2011 | 190 | 0.020 |
Why?
|
| Anxiety | 1 | 2017 | 1179 | 0.020 |
Why?
|
| Social Support | 1 | 2013 | 560 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 3045 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 1972 | 0.020 |
Why?
|
| Child Behavior | 1 | 2011 | 243 | 0.020 |
Why?
|
| Term Birth | 1 | 2009 | 30 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2014 | 2231 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2016 | 4307 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 1085 | 0.020 |
Why?
|
| Semantics | 1 | 2009 | 58 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 764 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 410 | 0.020 |
Why?
|
| Achievement | 1 | 2008 | 41 | 0.020 |
Why?
|
| Nucleus Accumbens | 1 | 2008 | 61 | 0.020 |
Why?
|
| Neural Conduction | 1 | 2008 | 112 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2014 | 2843 | 0.020 |
Why?
|
| Family | 1 | 2011 | 736 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 2013 | 666 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2012 | 2588 | 0.020 |
Why?
|
| Neuronal Plasticity | 1 | 2009 | 304 | 0.020 |
Why?
|
| Internal Capsule | 1 | 2006 | 40 | 0.020 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2008 | 341 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 4053 | 0.020 |
Why?
|
| Seizures | 1 | 2011 | 989 | 0.020 |
Why?
|
| Hospitalization | 1 | 2014 | 2083 | 0.020 |
Why?
|
| Pattern Recognition, Visual | 1 | 2004 | 35 | 0.020 |
Why?
|
| Occipital Lobe | 1 | 2004 | 48 | 0.020 |
Why?
|
| Pedigree | 1 | 2007 | 1890 | 0.010 |
Why?
|
| Gyrus Cinguli | 1 | 2004 | 140 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2017 | 13658 | 0.010 |
Why?
|
| Image Enhancement | 1 | 2004 | 561 | 0.010 |
Why?
|
| Emotions | 1 | 2004 | 562 | 0.010 |
Why?
|
| Age Factors | 1 | 2009 | 5377 | 0.010 |
Why?
|
| Receptors, Androgen | 1 | 2002 | 878 | 0.010 |
Why?
|
| Gene Expression | 1 | 2002 | 3570 | 0.010 |
Why?
|